A prospective trial evaluating safety and efficacy of bevacizumab plus paclitaxel combination therapy in patients with HER2-negative metastatic breast cancer in routine oncology practice in Germany

Trial Profile

A prospective trial evaluating safety and efficacy of bevacizumab plus paclitaxel combination therapy in patients with HER2-negative metastatic breast cancer in routine oncology practice in Germany

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 11 Oct 2016 Results (n=2135) of a pooled analysis from ML21165, AVANTI and AVAREG studies assessing real-world effectiveness and safety in clinically important subgroups, presented at the 41st European Society for Medical Oncology Congress.
    • 01 Mar 2016 Final results (n=865) published in the Anticancer Research.
    • 01 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top